Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)

Exclusion Criteria

• •Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days
• •Any concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function
• •Treatment with mouse-antibodies in patients with evaluable disease and CA-125 progressive disease in the last 3 months. These patients are only eligible in case of measurable disease according to RECIST or cytological/histological proven relapse
• •More than two prior lines of chemotherapy.
• •Any chemotherapy or other systemic anti-cancer therapy within four weeks prior to randomization.
• •Radiation therapy within the last 4 weeks prior to randomization (with the exception of palliative radiotherapy